Compare BGIN & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGIN | AVXL |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.9M | 397.6M |
| IPO Year | 2025 | N/A |
| Metric | BGIN | AVXL |
|---|---|---|
| Price | $2.98 | $4.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 46.8K | ★ 2.3M |
| Earning Date | 02-22-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $205,457,324.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.38 | $2.86 |
| 52 Week High | $6.50 | $14.25 |
| Indicator | BGIN | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 53.08 |
| Support Level | N/A | $3.50 |
| Resistance Level | N/A | $4.37 |
| Average True Range (ATR) | 0.00 | 0.25 |
| MACD | 0.00 | 0.14 |
| Stochastic Oscillator | 0.00 | 89.14 |
BGIN Blockchain Ltd is operating through its subsidiaries and is engaged in digital asset technology company based in Singapore, Hong Kong and the U.S. with proprietary cryptocurrency-mining technologies and a strategic focus on alternative cryptocurrencies. It design and sell mining machines equipped with proprietary 8nm or 12nm ASIC chips under different series dedicated to the mining of KAS coins, ALPH coins, and RXD coins. The Company operated in two reportable segments, which were the cryptocurrency mining and the sale of mining machines Key revenue is generated from Sale of mining machines. Geographically, It derives key revenue from Hong Kong, China and Vietnam, United States, Singapore, etc.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.